Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 494 clinical trials
Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

The primary objective of this study is to demonstrate the non-inferiority of the vaccine seroresponse to meningococcal serogroups A, C, Y, and W following administration of 2 doses of MenACYW conjugate vaccine compared to 2 doses of MENVEO when given concomitantly with routine pediatric vaccines to infants and toddlers 6 …

  • 0 views
  • 04 Dec, 2020
  • 47 locations
Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico

Primary Objective: To describe the antibody titers to the antigens (meningococcal serogroups A, C, Y, and present in MenACYW conjugate vaccine or Menveo measured by serum bactericidal assay using human complement (hSBA), for Groups 1 and 2 when administered concomitantly with routine pediatric vaccines in healthy infants and toddlers in …

  • 0 views
  • 08 Dec, 2020
  • 9 locations
Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico (MET33)

Primary Objective: To describe the antibody titers to the antigens (meningococcal serogroups A, C, Y, and present in MenACYW conjugate vaccine or Menveo® measured by serum bactericidal assay using human complement (hSBA), for Groups 1 and 2 when administered concomitantly with routine pediatric vaccines in healthy infants and toddlers in …

Accepts healthy volunteers
  • 0 views
  • 17 Nov, 2021
  • 11 locations
  • None views
  • None views
  • None views
  • None views
  • None views
  • None views
  • None views